STOCK TITAN
  1. Home
  2. News
  3. SGEN

Seagen Inc - SGEN STOCK NEWS

Welcome to our dedicated page for Seagen news (Ticker: sgen), a resource for investors and traders seeking the latest updates and insights on Seagen stock.

Seagen Inc. (symbol: SGEN) is a pioneering biotechnology firm co-founded by Dr. Clay Siegall. The company is at the forefront of developing antibody-drug conjugates (ADCs) for cancer treatment. Seagen's technology leverages the precision of monoclonal antibodies to deliver potent cell-killing agents exclusively to cancer cells, aiming for higher efficacy and fewer side effects compared to traditional therapies.

Seagen’s flagship product, Adcetris® (brentuximab vedotin), marks a significant advancement in cancer treatment. In partnership with Takeda Pharmaceutical Company Limited, Adcetris® has received approval in over 55 countries. Seagen is broadening the horizons of Adcetris® through an extensive clinical development program, exploring its potential against various types of lymphoma and other cancers.

Beyond Adcetris®, Seagen boasts a robust pipeline of clinical-stage programs, including promising candidates like SGN-CD19A, SGN-CD33A, SGN-LIV1A, SGN-CD70A, ASG-22ME, ASG-15ME, and SEA-CD40. These innovative therapies aim to address unmet medical needs in oncology, offering new hope to patients worldwide.

Seagen has forged strategic alliances with several leading biotechnology and pharmaceutical companies, such as AbbVie, Agensys, and more, to further leverage its ADC technology. These collaborations enhance Seagen's research capabilities and accelerate the development of novel treatments.

The company's commitment to advancing cancer therapy is reflected in its continuous research, strong financial health, and strategic partnerships. Investors and stakeholders can stay updated with Seagen's latest developments, achievements, and market performance through regular news updates and financial reports.

News

Pfizer Completes Acquisition of Seagen

Rhea-AI Summary
Pfizer Inc. (NYSE: PFE) has completed the acquisition of Seagen Inc. (NASDAQ: SGEN) for $43 billion, solidifying its position as a leading oncology company. The acquisition brings Seagen's world-leading Antibody-Drug Conjugate (ADC) technology and four in-line medicines to Pfizer's oncology portfolio. Dr. Albert Bourla, Pfizer's Chairman and CEO, emphasizes the company's commitment to delivering breakthrough treatments for cancer, with Oncology expected to be a significant growth driver for Pfizer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
acquisition
-
News

Pfizer Receives All Required Regulatory Approvals to Complete the Acquisition of Seagen

Rhea-AI Summary
Pfizer Inc. (PFE) is set to close the acquisition of Seagen Inc. (SGEN) on December 14, 2023, after receiving all required regulatory approvals. The company also announced changes in its commercial organization to incorporate Seagen and improve focus, speed, and execution. Pfizer will host an analyst and investor call to discuss the acquisition, new commercial organization, and provide full-year 2024 financial guidance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
acquisition
-
News

ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 100% Progression Free Survival at 12 months in Phase 2 Trial of Patients with Early Stage Classical Hodgkin Lymphoma

Rhea-AI Summary
Seagen Inc. (NASDAQ: SGEN) announced encouraging results from a Phase 2 study evaluating ADCETRIS in combination with nivolumab and standard chemotherapy agents as first-line treatment for early and advanced stage classical Hodgkin lymphoma. The investigational regimen showed a clinically meaningful progression-free survival rate, favorable clinical outcomes, and a consistent safety profile, with no new safety signals observed. The study demonstrated an overall response and complete response rate of 98% and 93% respectively in early-stage cHL patients, and an overall response and complete response rate of 95% and 89% respectively in advanced-stage cHL patients. The PFS rate at 24 months for advanced-stage cHL patients was 88%. ADCETRIS has been a proven foundation of care for CD30-expressing lymphomas globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.2%
Tags
clinical trial
News

TUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-Trastuzumab Emtansine Improves Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer

Rhea-AI Summary
Seagen Inc. (Nasdaq: SGEN) announced positive data from the Phase 3 HER2CLIMB-02 clinical trial of TUKYSA® (tucatinib) in combination with ado-trastuzumab emtansine for patients with HER2-positive breast cancer. The combination showed a significant improvement in progression-free survival and objective response rate, with manageable adverse events. TUKYSA is already approved by the FDA for third-line metastatic HER2-positive breast cancer, and the trial results reinforce its clinical activity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.01%
Tags
none
-
News

FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

Rhea-AI Summary
Seagen Inc. (SGEN) and Astellas Pharma Inc. (4503) announced that the FDA accepted for priority review a supplemental Biologics License Application for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) as a combination therapy for the treatment of adult patients with locally advanced or metastatic urothelial cancer. The combination significantly extended overall survival and progression-free survival vs standard platinum-containing chemotherapy. If approved, it would be the first and only antibody-drug conjugate plus PD-1 inhibitor treatment alternative to chemotherapy in this patient population.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.23%
Tags
none
-
News

Seagen Highlights First Solid Tumor Data for an ADCETRIS® (brentuximab vedotin) Immunotherapy Combination and Preclinical Data for Novel CD30-Directed Antibody-Drug Conjugate at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Rhea-AI Summary
Seagen Inc. presented Phase 2 data for ADCETRIS in combination with pembrolizumab in non-small cell lung cancer and melanoma. The combination showed objective response rates of 8% and 14% in NSCLC, and 18% and 22% in melanoma. Disease control rates were 67% and 72% in NSCLC, and 71% and 80% in melanoma. The safety profile was consistent with previous studies. Preclinical data was also presented for SGN-35T, a novel ADC with potential for improved tolerability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.1%
Tags
clinical trial
News

New Data for ADCETRIS® (brentuximab vedotin) with Immunotherapy Combination in Hodgkin Lymphoma to be Featured at 2023 ASH Annual Meeting, and Seagen to Unveil Novel CD30-Directed Antibody-Drug Conjugate

Rhea-AI Summary
Seagen Inc. (NASDAQ: SGEN) announced that updated Phase 2 data for ADCETRIS in combination with nivolumab in early and advanced stage classical Hodgkin lymphoma will be presented at the 65th American Society of Hematology (ASH) Annual Meeting. The data will include 12- and 24-month progression free survival rates. Additionally, preclinical data for the investigational antibody-drug conjugate SGN-35C will also be presented.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.2%
Tags
none
-
News

Seagen Third Quarter 2023 Financial Results Reflect Strong Product Sales Growth, and Significant Portfolio and Pipeline Progress

Rhea-AI Summary
Seagen Inc. reported record net product sales of $571 million in 3Q23, a 33% increase over 3Q22. PADCEV® in combination with Keytruda® demonstrated a near doubling of median overall survival in first-line metastatic urothelial cancer. The proposed Pfizer transaction is on-track to close in late-2023 or early-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.73%
Tags
earnings
-
News

TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial

Rhea-AI Summary
Seagen Inc. and Genmab A/S announced positive results from the Phase 3 innovaTV 301 trial, showing that TIVDAK demonstrated a 30% reduction in the risk of death in recurrent or metastatic cervical cancer patients compared to chemotherapy. TIVDAK also showed significant improvements in overall survival, progression-free survival, and objective response rate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
News

Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Line Advanced Bladder Cancer

Rhea-AI Summary
Seagen and Astellas announce positive results from Phase 3 clinical trial for enfortumab vedotin plus pembrolizumab in urothelial cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the market cap of Seagen (sgen)?

The market cap of Seagen (sgen) is approximately 43.2B.

What is Seagen Inc. known for?

Seagen Inc. is renowned for its innovative antibody-drug conjugates (ADCs) designed to treat cancer.

What is Adcetris®?

Adcetris® (brentuximab vedotin) is Seagen's lead ADC product, approved in over 55 countries for treating certain cancers.

Who founded Seagen Inc.?

Seagen Inc. was co-founded by Dr. Clay Siegall.

What recent projects is Seagen involved in?

Seagen is expanding the therapeutic applications of Adcetris® and advancing a pipeline of clinical-stage ADC therapies.

Which companies has Seagen partnered with?

Seagen has partnerships with Takeda, AbbVie, Agensys, and several other biotechnology and pharmaceutical companies.

How does Seagen's ADC technology work?

Seagen's ADCs use monoclonal antibodies to target and deliver cell-killing agents directly to cancer cells, minimizing damage to healthy cells.

What are some of Seagen’s clinical-stage programs?

Seagen's clinical-stage programs include SGN-CD19A, SGN-CD33A, SGN-LIV1A, SGN-CD70A, ASG-22ME, ASG-15ME, and SEA-CD40.

Where can I find the latest news about Seagen Inc.?

Latest news about Seagen Inc. can be found on their official website and financial news platforms like StockTitan.

What is the financial health of Seagen Inc.?

Seagen Inc. maintains strong financial health, supported by strategic partnerships and ongoing research initiatives.

How is Seagen expanding the use of Adcetris®?

Seagen is conducting extensive clinical trials to evaluate Adcetris® for various types of lymphoma and other cancers.
Stock SGEN logo
Seagen Inc

NYSE:SGEN

SGEN Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

SGEN Stock Data

43.15B
187.13M
0.81%
88.83%
5.08%
Biotechnology
Healthcare
Link
United States
Bothell